ADAM17 and neoplasm: In order to investigate whether ADAM17 may predict primary debulking efficiency, the proportion of patients without macroscopic tumor remnants (48 cases) was compared to those with residual tumor burden (35 cases), with regard to ADAM17 serum levels.